Arvinas Inc logo

ARVN

Arvinas Inc

$45.14

Earnings Summary

Revenue
$31.3Mn
Net Profits
$-70Mn
Net Profit Margins
-223.64%

Highlights

Revenue:

Arvinas Inc’s revenue jumped 464.53% since last year same period to $31.3Mn in the Q2 2022. On a quarterly growth basis, Arvinas Inc has generated 29.34% jump in its revenue since last 3-months.

Net Profits:

Arvinas Inc’s net profit fell -39.2% since last year same period to $-70Mn in the Q2 2022. On a quarterly growth basis, Arvinas Inc has generated -10.41% fall in its net profits since last 3-months.

Net Profit Margins:

Arvinas Inc’s net profit margin jumped 75.34% since last year same period to -223.64% in the Q2 2022. On a quarterly growth basis, Arvinas Inc has generated 14.64% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Arvinas Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.04
EPS Estimate Current Year
-1.04

Highlights

EPS Estimate Current Quarter:

Arvinas Inc’s earning per share (EPS) estimates for the current quarter stand at -1.04 - a -16.85% fall from last quarter’s estimates.

EPS Estimate Current Year:

Arvinas Inc’s earning per share (EPS) estimates for the current year stand at -1.04.

Key Ratios

Key ratios of the Arvinas Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.14
Return on Equity (ROE)
-0.37
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arvinas Inc’s return on assets (ROA) stands at -0.14.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arvinas Inc’s return on equity (ROE) stands at -0.37.

Dividend Per Share (DPS):

Arvinas Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.89
-1.2
-34.83%

Company Information

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Organisation
Arvinas Inc
Employees
179
Industry
Health Technology